Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Merger Agreement [Member]
Business Acquisition [Axis]
Merger Consideration [Member]
Legal Entity [Axis]
Asterias [Member]
Consolidated Entities [Axis]
Parent Company [Member]
Award Type [Axis]
Restricted Stock [Member]
Equity Components [Axis]
Common Stock [Member]
Ownership [Axis]
OncoCyte Corporation [Member]
Asterias Biotherapeutics, Inc. [Member]
Cell Cure Neurosciences Ltd [Member]
ES Cell International Pte., Ltd. [Member]
OrthoCyte Corporation [Member]
Title of Individual [Axis]
Controlled Equity Offering [Member]
Sales Agreement [Member]
Cantor Fitzgerald And Co Member [Member]
Investment, Name [Axis]
Antidilutive Securities [Axis]
Stock Options [Member]
Lineage Warrants [Member]
Restricted Stock Units [Member]
Accounting Standards Update [Axis]
Accounting Standards Update 2016-02 [Member]
ASC 840 [Member]
Related Party [Axis]
Majority Shareholder [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
In Process Research and Development [Member]
Royalty Contracts [Member]
California Institute for Regenerative Medicine [Member]
AST Clinical Program [Member]
Asterias Warrants [Member]
Lineage Warrants [Member]
Income Statement Location [Axis]
General and Administrative Expense [Member]
Asterias Biotherapeutics [Member]
OncoCyte Corporation and AgeX Therapeutics Inc [Member]
Stock Purchase Agreement [Member]
Juvenescence Limited [Member]
Scenario [Axis]
Closing of Transaction [Member]
Debt Instrument [Axis]
Promissory Note [Member]
Long-Lived Tangible Asset [Axis]
Equipment, Furniture and Fixtures [Member]
Leasehold Improvements [Member]
Right-of-Use Assets [Member]
Lease Contractual Term [Axis]
Lineage Terminated Lease [Member]
Goodwill And Intangible Assets By Major Class [Axis]
IPR&D - OPC1 [Member]
IPR&D - VAC2 [Member]
Patents [Member]
Research and Development Expense [Member]
Cancer Research [Member]
GBP [Member]
Axos Bank [Member]
Plan Name [Axis]
Paycheck Protection Program [Member]
Three Employees Member [Member]
Balance Sheet Location [Axis]
Cash and Cash Equivalents [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Marketable Securities [Member]
Cell Cure Warrants [Member]
Property Subject to or Available for Operating Lease [Axis]
Office space in New York City [Member]
Broadwood Partners, L.P [Member]
Neal Bradsher [Member]
2017 Sales Agreement [Member]
Statistical Measurement [Axis]
Maximum [Member]
Preferred Stock [Member]
Accumulated Deficit [Member]
Noncontrolling Inteests Deficit [Member]
AOCI Attributable to Parent [Member]
Hadasit Bio-Holdings Ltd. [Member]
Consultants [Member]
Minimum [Member]
2012 Equity Incentive Plan [Member]
Stock Option Plan of 2012 [Member]
Asterias 2013 Equity Incentive Plan [Member]
2012 Plan [Member]
Carlsbad Lease [Member]
Alameda Lease [Member]
Award Date [Axis]
First Twenty-Four Months [Member]
Thousand Ten Atlantic Premises [Member]
Thousand Twenty Atlantic Premises [Member]
Industrial Microbes, Inc [Member]
Alameda Sublease [Member]
Industrial Microbes Sublease [Member]
Cell Cure [Member]
Proceeds from Construction in Progress
NIS [Member]
December 31, 2018 Exchange Rate [Member]
January 2018 Lease [Member]
Operating Lease Liability [Member]
Finance Lease Liability [Member]
December 31, 2020 [Member]
December 31, 2021 [Member]
December 31, 2022 [Member]
December 31, 2023 [Member]
Research and Option Agreement [Member]
Orbit Biomedical Limited [Member]
Second Amendment [Member]
Gyroscope Therapeutics Limited [Member]
Upon Signing [Member]
November Thirty Two Thousand Twenty Twenty [Member]
License Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Future Years [Member]
Hadasit Bio Holdings [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS
Cash and cash equivalents
Marketable equity securities
Promissory note from Juvenescence (Note 5)
Trade accounts and grants receivable, net
Receivables from affiliates, net
Prepaid expenses and other current assets
Total current assets
NONCURRENT ASSETS
Property and equipment, net (Notes 6 and 15)
Deposits and other long-term assets
Goodwill
Intangible assets, net
TOTAL ASSETS
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable and accrued liabilities
Financing lease and right of use lease liabilities, current portion (Note 15)
Deferred revenues
Liability classified warrants, current portion
Total current liabilities
LONG-TERM LIABILITIES
Deferred tax liability
Deferred revenues, net of current portion
Right-of-use lease liability, net of current portion (Note 15)
Financing lease, net of current portion
Liability classified warrants, net of current portion
TOTAL LIABILITIES
Commitments and contingencies (Note 15)
SHAREHOLDERS’ EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of September 30, 2020 and December 31, 2019
Common shares, no par value, 250,000 shares authorized; 149,991 shares issued and outstanding as of September 30, 2020 and 149,804 shares issued and outstanding as of December 31, 2019
Accumulated other comprehensive loss
Accumulated deficit
Lineage Cell Therapeutics, Inc. shareholders’ equity
Noncontrolling deficit (Note 2)
Total shareholders’ equity
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
Preferred stock, no par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
REVENUES:
Grant revenue
Royalties from product sales and license fees
Sale of research products and services
Total revenues
Cost of sales
Gross profit
OPERATING EXPENSES:
Research and development
General and administrative
Total operating expenses
Loss from operations
OTHER INCOME/(EXPENSES):
Interest income, net
Gain on sale of marketable securities
Gain on sale of equity method in OncoCyte Corporation (“OncoCyte”)
Unrealized loss on marketable equity securities
Unrealized (loss)/gain on equity method investment in OncoCyte at fair value
Unrealized gain on equity method investment in Asterias at fair value
Unrealized gain on warrant liability
Other income, net
Total other (expense) income, net
LOSS BEFORE INCOME TAXES
Deferred income tax benefit
NET LOSS
Net loss attributable to noncontrolling interest
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.
NET LOSS PER COMMON SHARE:
BASIC
DILUTED
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC
DILUTED
NET LOSS
Other comprehensive loss, net of tax:
Foreign currency translation adjustment, net of tax
COMPREHENSIVE LOSS
Less: Comprehensive loss attributable to noncontrolling interest
COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC. COMMON SHAREHOLDERS
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage Cell Therapeutics, Inc.
Net loss allocable to noncontrolling interest
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Unrealized gain on equity method investment in OncoCyte at fair value
Unrealized gain on equity method investment in Asterias at fair value
Gain on sale of marketable securities
Unrealized loss on marketable equity securities
Deferred income tax benefit
Depreciation expense, including amortization of leasehold improvements
Amortization of right-of-use asset
Amortization of intangible assets
Stock-based compensation
Common stock issued for services
Gain on write-off and sales of assets
Change in unrealized gain on warrant liability
Write-off of security deposit
Amortization of deferred license fee
Foreign currency remeasurement and other gain
Changes in operating assets and liabilities:
Accounts and grants receivable, net
Accrued interest receivable
Receivables from OncoCyte and AgeX, net of payables
Prepaid expenses and other current assets
Accounts payable and accrued liabilities
Deferred revenue and other liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of OncoCyte common shares
Proceeds from the sale of AgeX common shares
Proceeds from the sale of Hadasit common shares
Cash and cash equivalents acquired in the Asterias Merger
Purchase of equipment and other assets
Proceeds from sale of equipment
Security deposits and other
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from payment of Juvenescence promissory note
Common shares received and retired for employee taxes paid
Reimbursement from landlord on tenant improvements
Proceeds from sales of common shares
Payments for offering costs
Repayment of financing lease liabilities
Proceeds from Paycheck Protection Program (“PPP”) Loan (Note 8)
Proceeds from sale of subsidiary warrants
Repayment of principal portion of promissory notes
Net cash provided by financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period
At end of the period
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Overview
Accounting Policies [Abstract]
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies
Business Combinations [Abstract]
Asterias Merger
Accounting For Common Stock Of Oncocyte At Fair Value
Accounting for Common Stock of OncoCyte, at Fair Value
Sale Of Significant Ownership Interest In Agex To Juvenescence Limited
Sale of Significant Ownership Interest in AgeX to Juvenescence Limited
Property, Plant and Equipment [Abstract]
Property and Equipment, Net
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities
Fair Value Disclosures [Abstract]
Fair Value Measurements
Related Party Transactions [Abstract]
Related Party Transactions
Equity [Abstract]
Shareholders’ Equity
Share-based Payment Arrangement [Abstract]
Stock-Based Awards
Income Tax Disclosure [Abstract]
Income Taxes
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Principles of consolidation
Liquidity
Business Combinations
Marketable Equity Securities
Revenue Recognition
Basic and diluted net income (loss) per share attributable to common shareholders
Restricted Cash
Lease accounting and impact of adoption of the new lease standard
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted
Schedule of Lineage's Ownership of Outstanding Shares of its Subsidiaries
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Schedule of Merger Consideration Transferred
Schedule of Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed
Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives
Schedule of Property and Equipment, Net
Schedule of Goodwill and Intangible Assets, Net
Schedule of Accounts Payable and Accrued Liabilities
Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis
Schedule of Shareholders' Equity
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity and Other Stock Options
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options
Schedule of Stock Based Compensation Expense
Schedule of Supplemental Cash Flow Information
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule of Supplemental Balance Sheet Information Related to Leases
Schedule of Future Minimum Lease Commitments
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of cell therapy programs
Ownership percentage
Stock-for-stock transaction
Aggregate merger consideration amount
Number of shares owned
Statement [Table]
Business Acquisition [Line Items]
Field of business description
Lineage ownership
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount
Restricted cash included in deposits and other long-term assets (see Note 15)
Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows
Entity Listings [Line Items]
Obligated common shares
[custom:RetainedEarningAccumulatedDeficit-0]
Working capital
[custom:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1-0]
Cash, Cash Equivalents, and Short-term Investments
Ownership percentage, description
Number of stock sold
Contract with Customer, Liability
Lease payment rate, description
Leasehold improvements, book value
Corresponding lease liabilities
Lease cumulative effect adjustment
Schedule of Equity Method Investments [Table]
Schedule of Equity Method Investments [Line Items]
Outstanding Asterias common stock
Exchange ratio
Lineage common shares issuable
Per share price of Lineage common shares
Purchase price
Number of restricted stock vested
Number of shares issued
Ownership interest
Schedule of Business Acquisitions, by Acquisition [Table]
Cash and cash equivalents
Prepaid expenses and other assets, current and noncurrent
Machinery and equipment
Long-lived intangible assets - royalty contracts
Acquired in-process research and development ("IPR&D")
Total assets acquired
Accrued liabilities and accounts payable
Liability classified warrants
Deferred license revenue
Long-term deferred income tax liability
Total liabilities assumed
Net assets acquired, excluding goodwill (a)
Fair value of Lineage common shares held by Asterias (b)
Total purchase price (c)
Estimated goodwill (c-a-b)
Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]
Acquired Finite-Lived Intangible Assets [Line Items]
Asset Fair Value
Useful Life (Years)
Closing price of common stock
Identifiable intangible asset acquired
Intangible asset, useful life
Upfront payment received
Estimated purchase price
Number of warrants issued to purchase of common stock
Exercise price
Warrant expiration date
Fair value of warrants percentage
Fair Value Adjustment of Warrants
Exchange of shares
Exchange for cash
Common stock held in investment
Share price, per share
Acquisition related costs
Fair value of equity method investment, shares
Fair value calculation, description
Fair value of equity method investment, value
Unrealized loss
Number of stock sold, value
Reduction in ownership percentage
Number of shares owned
Fair value on investment
Closing price per share
Unrealized Gain (Loss) on Investments
Equity Method Investment, Realized Gain (Loss) on Disposal
Unrealized loss on equity method investment related to book cost basis
Number of shares remaining for sales
Unrealized gain loss on equity method investment
Number of share sold
Sale of stock price per share
Purchase price of shares
Purchase price amount paid
Indemnity cap
Debt instrument interest rate
Debt instrument maturity date
Interest income debt
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property and equipment, gross
Accumulated depreciation and amortization
Property and equipment, net
Lessee, Lease, Description [Table]
Lessor, Lease, Description [Line Items]
Financing leases related to property and equipment
Right-of-use assets
Depreciation, Depletion and Amortization
Proceeds from Sale of Property, Plant, and Equipment
Gain (Loss) on Disposition of Property Plant Equipment
Gain on sale of non-capitalized assets
Statement [Line Items]
Total intangible assets
Accumulated amortization
Schedule of Goodwill [Table]
Goodwill [Line Items]
Accounts payable
Accrued compensation
Accrued liabilities
PPP loan payable
Other current liabilities
Total
Accounts payable
Accrued expenses
Signature fee
Proceeds from Loans
Percentage of non payroll costs
Separation payments
Description of termination plan
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Liabilities
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrealized gain recognized on warrant
Markup rate on allocated costs
Term of payment
Interest rate charged on unpaid and overdue invoices
Usage fee
Offset against general and administrative expenses
Offset against research and development expenses
Rent per month
Area of office space square feet
Lease expires date
Shares issued for settlement of warrants in connection with merger
Legal expenses
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
BALANCE AT JULY 1, 2019
Balance, shares
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees taxes, shares
Stock-based compensation
Foreign currency translation gain (loss)
Financing related fees
Shares issued in connection with the Asterias Merger
Shares issued in connection with the Asterias Merge, shares
Shares retired in connection with the Asterias Merger
Shares retired in connection with the Asterias Merger, shares
Shares issued for services
Shares issued for services, shares
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares
Adjustment upon adoption of leasing standard
Shares issued for settlement of Lineage Warrants
Shares issued for settlement of Lineage Warrants, shares
Shares issued through ATM
Shares issued through ATM, shares
Dissolution of BioTime Asia
BALANCE AT SEPTEMBER 30, 2019
Balance, shares
Preferred shares, shares authorized
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, issued
Common Stock, Shares, Outstanding
Aggregate offering price
Share value available for sale
Percentage of commission payable
Warrants issued to purchase ordinary shares
Warrants exercisable term
Warrants exercise price per share
Warrant expiration date
Warrants expiring period, description
Shares Available for Grant, Beginning balance
Number of Options Outstanding, Beginning balance
Number of RSUs Outstanding, Beginning balance
Weighted Average Exercise Price of Options Outstanding, beginning balance
Shares Available for Grant, Restricted stock units vested
Number of Options Outstanding, Restricted stock units vested
Number of RSUs Outstanding, Restricted stock units vested
Weighted Average Exercise Price of Options, Restricted stock units vested
Shares Available for Grant, Options granted
Number of Options Outstanding, Options granted
Number of RSUs Outstanding, Options granted
Weighted Average Exercise Price of Options Outstanding, Options granted
Shares Available for Grant, Options Exercised
Number of Options Outstanding, Options exercised
Number of RSUs Outstanding, Options exercised
Weighted Average Exercise Price of Options, Options exercised
Shares Available for Grant, Options expired/forfeited/cancelled
Number of Options Outstanding, Options expired/forfeited/cancelled
Number of RSUs Outstanding, Options expired/forfeited/cancelled
Weighted Average Exercise Price of Options Outstanding, Options expired/forfeited/cancelled
Shares Available for Grant, Beginning balance
Number of Options Outstanding, Ending balance
Number of RSUs Outstanding, Ending balance
Weighted Average Exercise Price of Options Outstanding, end balance
Number of Options Outstanding, Options exercisable
Weighted Average Exercise Price of Options Outstanding, Options exercisable
Shares Available for Grant, Beginning balance
Number of Options Outstanding, Beginning balance
Shares Available for Grant, Options granted
Weighted Average Exercise Price of Options Outstanding, Options exercised
Shares Available for Grant, Options expired/forfeited/cancelled
Shares Available for Grant, Ending balance
Expected life (in years)
Risk-free interest rates
Volatility
Dividend yield
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense
Number of shares available for grant
Options granted term
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Stock Issued During Period, Shares, New Issues
Deferred Tax Liabilities, Gross
Deferred Tax Assets, Valuation Allowance
Income Tax Expense (Benefit)
Deferred income Tax expens benefit
Schedule of Restructuring and Related Costs [Table]
Acquired Indefinite-lived Intangible Assets [Line Items]
Cash paid during period for interest
Issuance of common shares for the Asterias Merger
Assumption of liabilities in the Asterias Merger
Assumptions of warrants in the Asterias Merger
Issuance of common shares for settlement of Lineage Warrants
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from financing leases
Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from financing leases
Right of use assets obtained in exchange for lease obligations: Operating leases
Right of use assets obtained in exchange for lease obligations: Financing leases
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Right-of-use assets, net
Right-of-use lease liabilities, current
Right-of-use lease liabilities, noncurrent
Total operating lease liabilities
Property and equipment, gross
Accumulated depreciation
Property and equipment, net
Current liabilities
Long-term liabilities
Total finance lease liabilities
Operating Lease, Weighted Average Remaining Lease Term
Finance Lease, Weighted Average Remaining Lease Term
Weighted average discount rate Operating leases
Weighted average discount rate Finance leases
2020
2020
2021
2021
2022
2022
2023
2023
2024
2024
Thereafter
Thereafter
Total lease payments
Total lease payments
Less imputed interest
Less imputed interest
Total
Total
Rentable area
Lease commencement date
Lease expiration date
Base rent
Base rent increase rate
Security deposit
Number of buildings for lease, description
Security deposit reduction in value
Lease area
Termination fees
Reduction of contractual obligations
Lease, renewal term
Construction allowances of leasehold improvements
Base rent and construction allowance per month
Deposit
Future minimum payments
Access fees payable
Access fees
Agreed signature fee amount
Extension fees
Loss Contingency, Damages Awarded, Value
Clinical regulatory milestone
Sales related milestones
Royalty percentage
Milestone aggregate amount
Minimum annual maintenance fees
Subsequent Event [Table]
Subsequent Event [Line Items]
Sale of shares
Proceeds from sale of common stock
Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants.
Liability classified warrants, current portion.
Aggregated carrying amounts of obligations as of the balance sheet date Liability classified warrants and other long-term liabilities.
Grant revenue.
Royalties from product sales and license fees.
Sale of research products and services.
Amount of gain (loss) on sale or disposal of an equity method investment.
Unrealized (loss) gain on warrant liability.
Amount of gain (loss) on sale or disposal of an equity method investment.
Gain on sale of marketable securities.
Change in unrealized gain on warrant liability.
Write-off of security deposit.
Proceeds from the sale of common shares.
Proceeds from the sale of common shares.
Proceeds from the sale of common shares.
Common shares received and retired for employee taxes paid.
Reimbursement from landlord on tenant improvements.
Repayment of financing lease liabilities.
Proceeds from Paycheck Protection Program ("PPP") Loan (Note 8)
Payments for Proceeds from sale of subsidiary warrants.
Marketable securities unrealized loss.
Amount of foreign currency remeasurement realized and unrealized (gain) loss recognized and other in the income statement.
Security deposit paid and other.
Number of cell therapy programs.
Merger Agreement [Member]
Merger Consideration [Member]
Asterias [Member]
Number of shares owned.
OncoCyte Corporation [Member]
Liquidity [Policy Text Block]
Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]
Obligated common shares.
Controlled Equity Offering [Member]
Sales Agreement [Member]
Cantor Fitzgerald And Co Member [Member]
Working capital.
Ownership percentage, description.
Corresponding lease liabilities.
Lease cumulative effect adjustment.
ASC 840 [Member]
Retained Earnings (Accumulated Deficit)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest.
Field of business description.
Asterias Biotherapeutics, Inc. [Member]
Cell Cure Neurosciences Ltd [Member]
Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.
OrthoCyte Corporation [Member]
Stock Options [Member]
Lineage Warrants [Member]
Restricted Stock Units [Member]
California Institute for Regenerative Medicine [Member]
AST Clinical Program [Member]
Description of ntangible asset, useful life.
Royalty Contracts [Member]
Upfront payment received.
Asterias Warrants [Member]
Fair value of warrants percentage.
Exchange of shares.
Exchange for cash.
Lineage Warrants [Member]
Common stock held in investment.
Fair value of Equity method investment, shares.
Fair value calculation, description.
Asterias Biotherapeutics [Member]
Exchange ratio.
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed acquired at the acquisition date.
The amount of long-lived intangible assets - royalty contract recognized as of the acquisition date.
Amount of liability classified warrants due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives [Table Text Block]
Equipment, Furniture and Fixtures [Member]
Right-of-Use Assets [Member]
Accounting for Common Stock of Fair Value [Text Block]
OncoCyte Corporation and AgeX Therapeutics Inc [Member]
Reduction in ownership percenatge.
Unrealized loss on equity method investment related to book cost basis.
Number of shares remaining for sales.
Financing leases related to property and equipment.
Lineage Terminated Lease [Member]
Gain on sale of non-capitalized assets .
Unrealized gain loss on equity method investment
Goodwill And Intangible Assets By Major Class [Axis]
IPR&D - OPC1 [Member]
IPR&D - VAC2 [Member]
Patents [Member]
Accumulated amortization.
Stock Purchase Agreement [Member]
Juvenescence Limited [Member]
Closing of Transaction [Member]
Promissory Note [Member]
Indemnity cap.
Interest income debt.
Sale of Significant Ownership Interest [Text Block]
Cancer Research [Member]
Signature fee.
GBP [Member]
Axos Bank [Member]
Paycheck Protection Program [Member]
Percentage of forgiven amount.
Three Employees Member [Member]
Description of termination plan.
Unrealized loss recognized on warrant.
Unrealized gain recognized on warrant.
Cell Cure Warrants [Member]
Cash and Cash Equivalents [Member]
Marketable Securities [Member]
The percentage markup of the fee for the services and usage of facilities, equipment, and supplies aforementioned which shall be paid by the entity under Shared Facilities Agreement.
Represents the maximum number of days upon the receipt of an invoice within which the invoice must be paid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Represents the percentage of interest charged on invoices not paid when due.
Usage fee.
Offset against general and administrative expenses.
Offset against research and development expenses.
Office space in New York City [Member]
Lease Expiration Date.
Shares issued for settlement of warrants in connection with merger.
Broadwood Partners, L.P [Member]
Neal Bradsher [Member]
Financing related fees.
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services.
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares
Adjustment upon adoption of leasing standard.
Shares issued for settlement of warrants.
Shares issued for settlement of warrants, shares.
Maximum aggregate offering price of shares under sales agreement.
2017 Sales Agreement [Member]
Refers to a commission payable to the seller as a percentage of gross proceeds from the sale of shares of the entity.
Refers to term of warrants to exercise, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Hadasit Bio-Holdings, Ltd [Member]
Warrant expiration date.
Consultants [Member]
Warrants expiring period, description.
Schedule Of Share Based Compensation Employee Stock Option Purchase Plan Activity [Table Text Block]
2012 Equity Incentive Plan [Member]
Options granted term.
Asterias 2013 Equity Incentive Plan [Member]
Stock Option Plan of 2012 [Member]
Shares Available for Grant, Restricted stock units vested.
Shares Available for Grant, Options granted.
Number of RSUs Outstanding.
Number of Options Outstanding, Restricted stock units vested
Number of RSUs Outstanding, Restricted stock units granted.
Number of RSUs Outstanding, Restricted stock options exercised.
Number of RSUs Outstanding, Restricted stock units forfeited/cancelled.
2012 Plan [Member]
Assumption of liabilities in the Asterias Merger.
Assumptions of warrants in the Asterias Merger.
Operating cash flows from financing leases.
Operating Lease Liability [Member]
Property and equipment, gross.
Accumulated depreciation.
Property and equipment, net.
Finance leases liability current.
Finance Lease Liability [Member]
Carlsbad Lease [Member]
Date which lease or group of leases is set to commence, in CCYY-MM-DD format.
Refers to the base monthly rent as per lease agreement.
Alameda Lease [Member]
This refer to base rent increase rate per year as per lease agreement.
First Twenty-Four Months [Member]
Description on number of buildings for lease.
Thousand Ten Atlantic Premises [Member]
Thousand Twenty Atlantic Premises [Member]
Refers to value by which the security deposit has been reduced after first twenty-four months of lease term.
Industrial Microbes, Inc [Member]
Alameda Sublease [Member]
Termination fees.
Industrial Microbes Sublease [Member]
Contractual obligations.
Cell Cure [Member]
Office and Laboratory Space, Jerusalem, Israel [Member]
Represents the number of years for which the lease can be extended.
NIS [Member]
December 31, 2018 Exchange Rate [Member]
Lessee operating lease renewal term description.
Base rent and construction allowance per month.
January 2018 Lease [Member]
December 31, 2020 [Member]
December 31, 2021 [Member]
December 31, 2022 [Member]
December 31, 2023 [Member]
Access fees payable.
Research and Option Agreement [Member]
Orbit Biomedical Limited [Member]
Access fees.
Agreed signature fee amount.
Second Amendment [Member]
Gyroscope Therapeutics Limited [Member]
Extension fees.
Upon Signing [Member]
Latter of October 30, 2020 [Member]
Minimum annual maintenance fees.
Future Years [Member]
Milestone aggregate amount.
Royalty percentage.
Sales related milestones.
License Agreement [Member]
Clinical regulatory milestone.
Hadasit Bio Holdings [Member]
Weighted Average Exercise Price of Options, Restricted stock units vested
Number of non vested options outstanding.
November Thirty Two Thousand Twenty Twenty [Member]
Amortization of deferred license fee.
Payments for offering costs.
Deferred income Tax expens benefit.
Percentage of non payroll costs.
Reduction of contractual obligations.
Lineage Warrants [Member] [Default Label]
Assets, Current
Liabilities, Current
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Revenue from Contract with Customer, Including Assessed Tax
Cost of Revenue
Gross Profit
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Diluted
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
UnrealizedGainLossOnInvestmentsOne
MarketableSecuritiesGain
Marketable securities unrealized loss
Gain (Loss) on Disposition of Assets for Financial Service Operations
ChangeInUnrealizedGainOnWarrantLiability
AmortizationOfDeferredLicenseFee
Foreign currency remeasurement and other (gain) loss
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Accrued Interest Receivable, Net
Increase (Decrease) Due from Affiliates
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Security deposit paid and other
Net Cash Provided by (Used in) Investing Activities
CommonSharesReceivedAndRetiredForEmployeeTaxesPaid
PaymentsForOfferingCosts
RepaymentOfFinancingLeaseLiabilities
Repayments of Debt
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Investment Owned, Balance, Shares
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accounts Payable
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
Warrant expiration date [Default Label]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Percentage Of Markup Fee Allocated But Not Charged
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
Finance Lease, Liability, to be Paid, Year One
Finance Lease, Liability, to be Paid, Year Two
Finance Lease, Liability, to be Paid, Year Three
Finance Lease, Liability, to be Paid, Year Five
Finance Lease, Liability, to be Paid, after Year Five
Finance Lease, Liability, Payment, Due
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, Undiscounted Excess Amount